Hypoxic preconditioning of stem cells as a new approach to increase the efficacy of cell therapy for myocardial infarction

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 12, 2013, Pages 16-25

  Maslov, L N ^a   Podoksenov, Yu K ^a   Portnichenko, A G ^b   Naumova, A V ^c  

^a CARDIOLOGY RESEARCH INSTITUTE   (Russian Federation)

^b BOGOMOLETZ INSTITUTE OF PHYSIOLOGY   (Ukraine)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Heart; Hypoxic preconditioning; Ischemia; Stem cells

Indexed keywords

CHEMOKINE RECEPTOR CXCR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MET PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR; VASCULOTROPIN A;

ANIMAL; ANIMAL MODEL; ANOXIA; ARTICLE; BIOLOGICAL MODEL; GRAFT SURVIVAL; HEART INFARCTION; HUMAN; ISCHEMIC PRECONDITIONING; METABOLISM; METHODOLOGY; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; STEM CELL; STEM CELL TRANSPLANTATION;

ANIMALS; ANOXIA; GRAFT SURVIVAL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISCHEMIC PRECONDITIONING; MODELS, ANIMAL; MODELS, CARDIOVASCULAR; MYOCARDIAL INFARCTION; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, CXCR; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84898652757     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: 10.15690/vramn.v68i12.855     Document Type: Article

References (81)

1. Suleiman M., Aronson D., Reisner S.A. et al. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am. J. Med. 2003; 115 (9): 695-701.
2. Solomon S.D., St John Sutton M., Lamas G. et al. Survival And Ventricular Enlargement (SAVE) Investigators. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation. 2002; 106 (10): 1251-1255.
3. Richards A.M., Nicholls M.G., Troughton R.W. et al. Antecedent hypertension and heart failure after myocardial infarction. J. Am. Coll. Cardiol. 2002; 39 (7): 1182-1188.
4. Parodi G., Carrabba N., Santoro G.M. et al. Heart failure and left ventricular remodeling after reperfused acute myocardial infarction in patients with hypertension. Hypertension. 2006; 47 (4): 706-710.
5. Araszkiewicz A., Lesiak M., Grajek S. et al. Relationship between tissue reperfusion and postinfarction left ventricular remodelling in patients with anterior wall myocardial infarction treated with primary coronary angioplasty. Kardiol. Pol. 2006; 64 (4): 383-388.
6. Soonpaa M.H., Field L.J. Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse hearts. Am. J. Physiol. 1997; 272 (1 Pt. 2): H220-H226.
7. Quaini F., Cigola E., Lagrasta C. et al. End-stage cardiac failure in humans is coupled with the induction if proliferating cell nuclear antigen and nuclear mitotic division in ventricular myocytes. Circ. Res. 1994; 75 (6): 1050-1063.
8. Reiss K., Kajstura J., Zhang X., Li P. et al. Acute myocardial infarction leads to upregulation of the IGF-1 autocrine system, DNA replication, and nuclear mitotic division in the remaining viable cardiac myocytes. Exp. Cell. Res. 1994; 213 (2): 463-472.
9. Beltrami A.P., Urbanek K., Kajstura J. et al. Evidence that human cardiac myocytes divide after myocardial infarction. N. Engl. J. Med. 2001; 344 (23): 1750-1757.
10. Hsieh P.C., Segers V.F., Davis M.E. et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nature Med. 2007; 13 (8): 970-974.
11. Neckar J., Ostadal B., Kolar F. Acute but not chronic tempol treatment increases ischemic and reperfusion ventricular arrhythmias in open-chest rats. Physiol. Res. 2008; 57 (4): 653-656.
12. Marelli D., Desrosiers C., el-Alfy M. et al. Cell transplantation for myocardial repair: An experimental approach. Cell Transplant. 1992; 1 (6): 383-390.
13. Chiu R.C., Zibaitis A., Kao R.L. Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation. Ann. Thorac. Surg 1995; 60 (1): 12-18.
14. Koh G.Y., Klug M.G., Soonpaa M.H., Field L.J. Differentiation and long-term survival of C2C12 myoblast grafts in heart. J. Clin. Invest. 1993; 92 (3): 1548-1554.
15. Grounds M.D., White J.D., Rosenthal N., Bogoyevitch M.A. The role of stem cells in skeletal and cardiac muscle repair. J. Histochem. Cytochem. 2002; 50 (5): 589-610.
16. Hughes S. Cardiac stem cells. J. Physiology. 2002; 197 (4): 468-478.
17. Orlic D., Hill J.M., Arai A.E. Stem cells for myocardial regeneration. Circ. Res. 2002; 91 (12): 1092-1102.
18. Toma C., Pittenger M.F., Cahill K.S. et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002; 105 (1): 93-98.
19. Murry C.E., Soonpaa M.H., Reinecke H. et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004; 428 (6983): 664-668.
20. Balsam L.B., Wagers A.J., Christensen J.L. et al. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature. 2004; 428 (6983): 668-673.
21. Limbourg F.P., Ringes-Lichtenberg S., Schaefer A. et al. Haematopoietic stem cells improve cardiac function after infarction without permanent cardiac engraftment. Eur. J. Heart Fail. 2005; 7 (5): 722-729.
22. Bianco P., Cao X., Frenette P.S. et al. The meaning, the sense and the significance: Translating the science of mesenchymal stem cells into medicine. Nat. Med. 2013; 19 (1): 35-42.
23. Yoshioka T., Ageyama N., Shibata H. et al. Repair of infarcted myocardium mediated by transplanted bone marrow-derived CD34+ stem cells in a nonhuman primate model. Stem Cells 2005; 23 (3): 355-364.
24. Mirotsou M., Zhang Z., Deb A. et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc. Natl Acad. Sci. USA 2007; 104 (5): 1643-1648.
25. Fazel S., Cimini M., Chen L., Li S. et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J. Clin. Invest. 2006; 116 (7): 1865-1877.
26. Uemura R., Xu M., Ahmad N., Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ. Res. 2006; 98 (11): 1414-1421.
27. Abkowitz J.L., Catlin S.N., McCallie M.T., Guttorp P. Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. Blood. 2002; 100 (7): 2665-2667.
28. Hatzistergos K.E., Quevedo H., Oskouei B.N. et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ. Res. 2010; 107(7): 913-922.
29. Bittner R.E., Schofer C., Weipoltshammer K. et al. Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. Anat. Embryol. 1999; 199 (5): 391-396.
30. Quaini F., Urbanek K., Beltrami A.P. et al. Chimerism of the transplanted heart. N. Engl. J. Med. 2002; 346 (1): 5-15.
31. Hruban R.H., Long P.P., Perlman E.J. et al. Fluorescence in situ hybridization for the Y-chromosome can be used to detect cells of recipient origin in allografted hearts following cardiac transplantation. Am. J. Pathol. 1993; 142 (4): 975-980.
32. Strauer B.E., Brehm M., Zeus T. et al. Repair of infracted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002; 106 (15): 1913-1918.
33. Strauer B.E., Kornowski R. Stem cell therapy in perspective. Circulation. 2003; 107 (7): 929-934.
34. Assmus B., Schachinger V., Teupe C. et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation. 2002; 106 (24): 3009-3017.
35. Britten M.B., Abolmaali N.D., Assmus B. et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation. 2003; 108 (18): 2212-2218.
36. Dobert N., Britten M., Assmus B. et al. Transplantation of progenitor cells after reperfused acute myocardial infarction: evaluation of perfusion and myocardial viability with FDG-PET and thallium SPECT. Eur. J. Nucl. Med. Mol. Imaging. 2004; 31 (8): 1146-1151.
37. Das R., Jahr H., van Osch G.J., Farrell E. The role of hypoxia in bone marrow-derived mesenchymal stem cells: considerations for regenerative medicine approaches. Tissue Eng. Part B Rev. 2010; 16 (2): 159-168.
38. Herrmann J.L., Abarbanell A.M., Weil B.R. et al. Optimizing stem cell function for the treatment of ischemic heart disease. J. Surg. Res. 2011; 166 (1): 138-145.
39. Rosova I., Dao M., Capoccia B. et al. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells. 2008; 26 (8): 2173-2182.
40. Hu X., Wei L., Taylor T.M. et al. Hypoxic preconditioning enhances bone marrow mesenchymal stem cell migration via Kv2.1 channel and FAK activation. Am. J. Physiol. Cell. Physiol. 2011; 301 (2): C362-C372.
41. 2, and pressure studied in dogs. Acta Orthop. Scand. 1985; 56 (5): 400-403.
42. Tsai C.C., Yew T.L., Yang D.C. et al. Benefits of hypoxic culture on bone marrow multipotent stromal cells. Am. J. Blood Res. 2012; 2 (3): 148-159.
43. Tang Y.L., Zhu W., Cheng M. et al. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ. Res. 2009; 104 (10): 1209-1216.
44. Akita T., Murohara T., Ikeda H. et al. Hypoxic preconditioning augments efficacy of human endothelial progenitor cells for therapeutic neovascularization. Lab. Invest. 2003; 83 (1): 65-73.
45. Wang J.A., Chen T.L., Jiang J. et al. Hypoxic preconditioning attenuates hypoxia/reoxygenation-induced apoptosis in mesenchymal stem cells. Acta Pharmacol. Sin. 2008; 29 (1): 74-82.
46. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 2007; 87 (1): 99-163.
47. Chang C.P., Chio C.C., Cheong C.U. et al. Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury. Clin. Sci. (Lond). 2013; 124 (3): 165-176.
48. Hu X., Yu S.P., Fraser J.L. et al. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J. Thorac. Cardiovasc. Surg. 2008; 135 (4): 799-808.
49. Lishmanov Yu.B., Maslov L.N., Ugdyzhekova D.S., Smagin G.N. Participation of central kappa-opioid receptors in arrhythmogenesis. Life Sci. 1997; 61 (3): PL33-PL38.
50. Maslov L.N. The role of erythropoetin in ischemic preconditioning, postconditioning, and regeneration of the brain after ischemia. Neurosci. Behav. Physiol. 2011; 41 (4): 353-363.
51. Wang J.A., He A., Hu X. et al. Anoxic preconditioning: A way to enhance the cardioprotection of mesenchymal stem cells. Int. J. Cardiol. 2009; 133 (3): 410-412.
52. Wang Y., Luther K. Genetically manipulated progenitor/stem cells restore function to the infarcted heart via the SDF-1a/CXCR4 signaling pathway. Prog. Mol. Biol. Transl. Sci. 2012; 111: 265-284.
53. Liu H., Xue W., Ge G. et al. Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1α in MSCs. Biochem. Biophys. Res. Commun. 2010; 401 (4): 509-515.
54. Wei L., Fraser J.L., Lu Z.Y., Hu X., Yu S.P. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol. Dis. 2012; 46 (3): 635-645.
55. Liu H., Liu S., Li Y. et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS One. 2012; 7 (4): e34608.
56. Liu H., Yu X.F., Teng J. et al. Effects of hypoxic preconditioning on the migration of bone marrow derived mesenchymal stem cells. Zhonghua Yi Xue Za Zhi. 2012; 92 (10): 709-713.
57. Kim H.W., Haider H.K., Jiang S., Ashraf M. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J. Biol. Chem. 2009; 284 (48): 33161-33168.
58. Kim H.W., Mallick F., Durrani S. et al. Concomitant activation of miR-107/PDCD10 and Hypoxamir-210/Casp8ap2 and their role in cytoprotection during ischemic preconditioning of stem cells. Antioxid. Redox Signal. 2012; 17 (8): 1053-1065.
59. Chacko S.M., Ahmed S., Selvendiran K. et al. Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells. Am. J. Physiol. Cell Physiol. 2010; 299 (6): C1562-C1570.
60. Peterson K.M., Aly A., Lerman A. et al. Improved survival of mesenchymal stromal cell after hypoxia preconditioning: role of oxidative stress. Life Sci. 2011; 88 (1-2): 65-73.
61. Koopman G., Reutelingsperger C.P., Kuijten G.A. et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994; 84 (5): 1415-1420.
62. Sah N.K., Khan Z., Khan G.J., Bisen P.S. Structural, functional and therapeutic biology of survivin. Cancer Lett. 2006; 244 (2): 164-171.
63. Efimenko A., Starostina E., Kalinina N., Stolzing A. Angiogenic properties of aged adipose derived mesenchymal stem cells after hypoxic conditioning. J. Transl. Med. 2011; 9: 10.
64. Hollenbeck S.T., Senghaas A., Komatsu I. et al. Tissue engraftment of hypoxic-preconditioned adipose-derived stem cells improves flap viability. Wound Repair Regen. 2012; 20(6): 872-878.
65. Zhu H., Chen X., Deng L. Effects of hypoxic preconditioning on glucose metabolism of rat bone marrow mesenchymal stem cells. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2011; 25(8): 1004-1007.
66. Sen G.L., Wehrman T.S., Blau H.M. mRNA translation is not a prerequisite for small interfering RNA-mediated mRNA cleavage. Differentiation. 2005; 73(6): 287-293.
67. Ong L.L., Li W., Oldigs J.K. et al. Hypoxic/normoxic preconditioning increases endothelial differentiation potential of human bone marrow CD133+ cells. Tissue Eng. Part C Methods. 2010; 16 (5): 1069-1081.
68. Horn P.A., Tesch H., Staib P. et al. Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells. Blood. 1999; 93 (4): 1435-1437.
69. Peichev M., Naiyer A.J., Pereira D. et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood. 2000; 95 (3): 952-958.
70. Sanai N., Alvarez-Buylla A., Berger M.S. Neural stem cells and the origin of gliomas. N. Engl. J. Med. 2005; 353 (8): 811-822.
71. Oh J.S., Ha Y., An S.S. et al. Hypoxia-preconditioned adipose tissue-derived mesenchymal stem cell increase the survival and gene expression of engineered neural stem cells in a spinal cord injury model. Neurosci. Lett. 2010; 472 (3): 215-219.
72. De Barros S., Dehez S., Arnaud E., et al. Aging-related decrease of human ASC angiogenic potential is reversed by hypoxia preconditioning through ROS production. Mol. Ther. 2013; 21 (2): 399-408.
73. Stubbs S.L., Hsiao S.T., Peshavariya H.M. et al. Hypoxic preconditioning enhances survival of human adipose-derived stem cells and conditions endothelial cells in vitro. Stem Cells Dev. 2012; 21 (11): 1887-1896.
74. Jaussaud J., Biais M., Calderon J. et al. Hypoxia-preconditioned mesenchymal stromal cells improve cardiac function in a swine model of chronic myocardial ischaemia. Eur. J. Cardiothorac. Surg. 2013; 43 (5): 1050-1057.
75. Beltrami A.P., Barlucchi L., Torella D. et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003; 114 (6): 763-776.
76. Messina E., De Angelis L., Frati G. et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ. Res. 2004; 95 (9): 911-921.
77. Dawn B., Stein A.B., Urbanek K. et al. Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc. Natl. Acad. Sci. USA. 2005; 102 (10): 3766-3771.
78. Davis D.R., Zhang Y., Smith R.R. et al. Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue. PLoS One. 2009; 4 (9): e7195.
79. Yan F., Yao Y., Chen L. et al. Hypoxic preconditioning improves survival of cardiac progenitor cells: role of stromal cell derived factor-1α-CXCR4 axis. PLoS One. 2012; 7 (7): e37948.
80. Makkar R.R., Smith R.R., Cheng K. et al. Intracoronary cardiosphere- derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. Lancet. 2012; 379 (9819): 895-904.
81. Bolli R., Chugh A.R., D'Amario D. et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011; 378 (9806): 1847-1857.